Budget impact of Imlifidase
1 evidence topic · 1 source
Summary
The Irish NCPE assessment includes a five-year budget-impact analysis, distinct from its lifetime cost-effectiveness model. The budget analysis assumed approximately 20 eligible patients and four to five imlifidase-enabled transplants annually. It estimated gross drug expenditure of €8,721,695 and a net total budget impact of €5,376,092 after other healthcare costs and dialysis cost offsets. These estimates describe the Irish population, prices, and model assumptions, not a United States budget impact.